Xenikos Enrolls First Patient in Global Pivotal Phase 3

Study Designed to Evaluate Whether T-Guard is Superior to Ruxolitinib in Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host...

Related Keywords

Oregon ,United States ,Netherlands ,Paris ,France General ,France ,Nijmegen ,Gelderland ,John Levine ,Gabrielle Meyers ,Ypke Van Oosterhout ,Sam Martin Carrie Mckim ,Mehdi Hamadani ,Professor Of The Department Hematology ,National Cancer Institute ,Core Transplant Centers Consortia ,Marrow Transplant Research ,International Blood ,Oregon Health ,Clinical Research ,Blood Institute ,Sinai School Of Medicine ,National Heart ,Science University ,Emmes Company ,National Institutes Of Health ,Drug Administration ,National Marrow Donor Program ,College Of Wisconsin ,Marrow Transplant Clinical Trials Network ,Regulatory Agency ,European Medicines Agency ,Study Designed ,Evaluate Whethert Guard ,Results Expected First Half ,Surface Area ,Safety Monitoring Board ,Biologics License Application ,Marketing Authorization Application ,Protocol Co Chair ,Chief Executive Officer ,Sinai School ,Associate Professor ,Helping Reset ,Marrow Transplantation ,Orphan Drug Designation ,National Institutes ,Medical College ,Protocol Officer ,Scientific Director ,Xenikosbv ,